No Detail Found!

Efficacy and safety of colchicine in reducing cardiovascular mortality and cardiac injury among adult patients with coronary artery disease: A systematic review and meta-analysis

Author(s)
Darmadi Darmadi Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan
Herwindo Ahmad Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan
Cennikon Pakpahan Department of Biomedical Science, Faculty of Medicine, Universitas Airlangga, Surabaya,
Sem Samuel Surja Department of Parasitology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
Abstract
Objectives: To evaluate the efficacy and safety of colchicine in preventing adverse cardiovascular outcomes in adults with coronary artery disease (CAD). Methodology: This systematic review and meta-analysis were conducted by searching PubMed, Scopus, and the Cochrane Library databases. Randomized controlled trials (RCTs) assessing the effects of colchicine on cardiac mortality, cardiac injury, or adverse events in adults aged 18 years and older with CAD were included. Data extraction and risk of bias assessment were independently performed by two reviewers. Odds ratios (OR) with 95% confidence intervals (CI) were calculated for dichotomous outcomes, and mean differences (MD) for continuous outcomes. A random-effects model was applied to synthesize data. Results: Seven RCTs met the inclusion criteria and were analyzed. Colchicine treatment was associated with a statistically significant reduction in cardiovascular mortality (OR = 0.75; 95% CI, 0.60-0.92; p=0.007). However, the effects on cardiac injury markers were not statistically significant and demonstrated high heteroge-neity. Safety outcomes also showed no significant diffe-rence overall but revealed variability across studies. Some trials reported increased incidences of gastroin-testinal adverse effects, as well as elevations in liver enzymes (alanine aminotransferase) and muscle injury markers (creatine kinase), indicating potential hepatic and muscular side effects. Conclusion: Colchicine shows potential in significan-tly reducing cardiovascular mortality in adults with CAD. Nevertheless, its impact on cardiac injury and safety profiles remains inconclusive, highlighting the need for further standardized, high-quality trials to in-form clinical practice.
Publication Details
Page(s) 819-824
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Colchicine, Coronary artery disease, Systematic review, Meta-analysis., cardi-ovascular mortality
References
Vos T,Abajobir AA,Abate KH,Abbafati C,Abbas KM,Abdallah F .2017 .a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100) : 1211-59.
UlI RE,Satyana RP,Zomer E,Magliano D,Liew D .2020 .Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. BMJ open, 10 : e039221.
Poledniczek M,Neumayer C,KopP CW,Schlager O,GremmeL T,Jozkowicz A .2023 .Micro-. Macrovascular Effects of Inflammation in Peripheral Artery Disease-Pathophysiology and Translational Therapeutic Approaches. Biomedicines, 11 : 2284-7.
El-Hasbani G,Jawad A,Uthman I. Colchicine: .2021 .An ancient drug with multiple benefits. Curr Pharmaceut Design, 27 : 2917-24.
Cirillo P,Conte S,Pellegrino G,Barra G,De Palma R,Sugraliyev A .2022 .Effects of colchicine on tissue factor in oxldlactivated T-lymphocytes. J Thrombosis Thrombolysis, 53 : 1-11.
Ravelli RB,Gigant B,Curmi pa,Jourdain I,Lachkar S,Sobel A .2004 .Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature, 428 : 198-202.
Tardif ,Kouz S,Waters DD,Bertrand OF,Diaz R,Maggioni AP .2019 .Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med, 381 : 2497-505.
Al-Abdouh A,Barbarawi M,Khan SU,Osman M,Upadhrasta S,Solipuram V .2021 .Colchicine therapy in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Coronary Artery Dis, 32 : 441-7.
Ullah W,Gowda SN,Fischman D .2021 .Safety and efficacy of colchicine in patients with coronary artery disease: a systematic review and meta-analysis. Cardiovasc Revascularization Med, 23 : 1-6.
Page MJ,Mckenzie JE,Bossuyt PM,Boutron I,Hoffmann TC,Mulrow CD .2021 .The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372 : n71.
Sterne JA,Savović J,Page MJ,Elbers RG,Blencowe NS,Boutron I .2019 .Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366 : 14898.
West SL,Gartlehner G,Mansfield AJ,Poole C,Tant E,Lenfestey N . .Comparative effectiveness review methods: clinical heterogeneity. Agency for Healthcare Research and Quality (US), Rockville (MD); 2010. , 21433337 : .
Aslanabadi N,Khiali s,Joudi S,Mamdouhi M,Entezarimaleki T .2021 .Colchicine for the prevention of myocardial injury following elective PCI: a randomized clinical trial. Pharmaceut Sci, 28 : 596-602.
Pan T,Jiang C-Y,Zhang H,Han X-K H-T,Jiang XY .2023 .The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial. Crit Care, 27 : 49-54.
Sellakannu S,Sharma YP,Panda PK,Mehrotra S,Rana S,Sharma S .2023 .Effects of low dose colchicine in patients of Coronary artery disease undergoing percutaneous coronary intervention. Indian Heart J, 75 : S16-S7.
Shah B,Pillinger M,Zhong H,Cronstein B,Xia Y,Lorin JD .2020 .Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention. Circulation, 13(4) : e008717.
Tong DC,Quinn S,Nasis A,Hiew C,Roberts-thomson P,Adams H .2020 .Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation, 142 : 1890-900.
Van Broekhoven A,Mohammadnia N,Silvis MJ,Los J,Fiolet AT,Opstal TS .2022 .The effect of years-long exposure to low-dose colchicine on renal and liver function and blood creatine kinase levels: safety insights from the low-dose colchicine 2 (lodoco2) trial. Clin Drug Invest, 42 : 977-85.
Mewton N,Roubille F,Bresson D,Prieur C,Bouleti C,Bochaton T .2021 .. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 144 : 859-69.
Nidorf SM,Eikelboom JW,Budgeon CA,Thompson PL .2013 .Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol, 61 : 404-10.
Nidorf SM,Fiolet ATL,Mosterd A,Eikelboom JW,Schut A,Opstal TSJ .2020 .Colchicine in patients with chronic coronary disease. N Engl J Med, 383 : 1838-47.
Kofler T,Kurmann R,Lehnick D,Cioffi GM,Chandran S,Attinger‐toller A .2021 .Colchicine in patients with coronary artery disease: a systematic review and meta‐analysis of randomized trials. J Am Heart Assoc, 10 : e021198.
Chen T,Liu G,Yu B. .2023 .A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. Clin Res Cardiol, 112 : 1487-505.
Ma Z,Chen J,Jin K,Chen X .2022 .Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials. Front Cardiovasc Med, 9 : 947959.
Xu H,Mao L,Liu H,Lin Z,Zhang Y,Yang J .2022 .Colchicine for Secondary prevention of coronary artery disease: a metaanalysis of randomised controlled trials. Heart Lung Circulation, 31 : 685-95.
0

Citations

0

Downloads

67

Views